In a 20-year-old male with sickle cell disease presenting with an acute vaso‑occlusive crisis who was treated with intravenous fluids, morphine, and enoxaparin (low‑molecular‑weight heparin) and now has a platelet count of 80 × 10⁹/L with normal creatinine and urea, what is the most likely cause of his thrombocytopenia?

The Most Likely Cause is HIT (Heparin-Induced Thrombocytopenia)

In this 20-year-old male with sickle cell disease who developed thrombocytopenia (platelet count 80 × 10⁹/L) after receiving enoxaparin for vaso-occlusive crisis management, the answer is D: HIT (Heparin-induced thrombocytopenia).

Clinical Reasoning

The key diagnostic features pointing to HIT include:

Timing and Exposure

• The patient received enoxaparin (a low-molecular-weight heparin) during his acute presentation
• HIT typically develops between days 5-14 of heparin therapy, though it can occur earlier (even day 1) in patients with recent heparin exposure within the previous 3 months 1
• The thrombocytopenia is moderate (80 × 10⁹/L), which is characteristic of HIT—platelet counts typically remain > 20 G/L and often between 30-70 G/L 1

Exclusion of Other Diagnoses

Why NOT HUS or TTP (Options B and C):

• Both HUS and TTP present with microangiopathic hemolytic anemia, thrombocytopenia, and renal dysfunction
• This patient has normal creatinine and urea, effectively ruling out both conditions 1
• TTP would also typically present with neurological symptoms and more severe thrombocytopenia

Why NOT ITP (Option A):

• ITP is a diagnosis of exclusion with no clear precipitating factor
• The temporal relationship with enoxaparin administration makes HIT far more likely
• ITP typically presents with more profound thrombocytopenia (often < 30 × 10⁹/L)

HIT Pathophysiology in This Context

HIT is a clinical-biological syndrome induced by IgG antibodies that recognize heparin-modified platelet factor 4 (PF4/H), leading to intense platelet activation and thrombin generation 1. The thrombocytopenia results from:

• Massive platelet activation
• Elimination by the mononuclear phagocyte system
• Cells sensitized by PF4/heparin/IgG complexes 1

Risk Stratification

According to 2020 guidelines, LMWH (enoxaparin) in medical settings carries a LOW risk (< 0.1%) for HIT 1. However, the diagnosis must still be considered when thrombocytopenia develops in any patient receiving heparin products.

Immediate Management Required

The enoxaparin must be stopped immediately without waiting for laboratory confirmation 1. According to guidelines:

• Calculate the 4T score to assess pre-test probability (evaluates: Thrombocytopenia severity, Timing of onset, Thrombosis presence, and other causes) 1

• If pre-test probability is intermediate (4T = 4-5) or high (4T ≥ 6), immediately:

  • Stop all heparin products 1
  • Switch to non-heparin anticoagulant (argatroban, bivalirudin, danaparoid, or fondaparinux) 1
  • Order anti-PF4 antibody testing 1

• Since this patient has normal renal function, options include argatroban, bivalirudin, danaparoid, or fondaparinux 1

Critical Pitfalls to Avoid

1. Never delay stopping heparin while waiting for laboratory results—the decision is clinical 1
2. Do not use prophylactic doses of alternative anticoagulants; use therapeutic/curative doses 1
3. Monitor platelet count closely during transition to alternative anticoagulation 1
4. Be aware that HIT can occur with both UFH and LMWH, though risk is lower with LMWH 1

The combination of heparin exposure, moderate thrombocytopenia, and normal renal function makes HIT the most likely diagnosis requiring immediate intervention.